Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 2
1951 1
1952 2
1953 11
1954 3
1955 5
1956 13
1957 10
1958 2
1959 6
1960 1
1961 2
1962 6
1963 5
1964 3
1965 7
1966 7
1967 9
1968 7
1969 8
1970 10
1971 17
1972 8
1973 17
1974 5
1975 10
1976 8
1977 18
1978 14
1979 19
1980 15
1981 10
1982 11
1983 15
1984 11
1985 20
1986 7
1987 9
1988 14
1989 9
1990 14
1991 11
1992 14
1993 7
1994 7
1995 11
1996 7
1997 20
1998 17
1999 18
2000 22
2001 29
2002 19
2003 35
2004 21
2005 36
2006 31
2007 22
2008 31
2009 24
2010 24
2011 28
2012 35
2013 35
2014 36
2015 40
2016 33
2017 40
2018 46
2019 40
2020 61
2021 55
2022 46
2023 34
2024 36
2025 24

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,267 results

Results by year

Filters applied: . Clear all
Page 1
Germline CDH1 Variants and Lifetime Cancer Risk.
Ryan CE, Fasaye GA, Gallanis AF, Gamble LA, McClelland PH, Duemler A, Samaranayake SG, Blakely AM, Drogan CM, Kingham K, Patel D, Rodgers-Fouche L, Siegel A, Kupfer SS, Ford JM, Chung DC, Dowty JG, Sampson J, Davis JL. Ryan CE, et al. Among authors: siegel a. JAMA. 2024 Sep 3;332(9):722-729. doi: 10.1001/jama.2024.10852. JAMA. 2024. PMID: 38873722 Free PMC article.
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, Sarker D, Verset G, Chan SL, Knox J, Daniele B, Webber AL, Ebbinghaus SW, Ma J, Siegel AB, Cheng AL, Kudo M; KEYNOTE-224 investigators. Zhu AX, et al. Among authors: siegel ab. Lancet Oncol. 2018 Jul;19(7):940-952. doi: 10.1016/S1470-2045(18)30351-6. Epub 2018 Jun 3. Lancet Oncol. 2018. PMID: 29875066 Clinical Trial.
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder V, Edeline J, Chao Y, Ogasawara S, Yau T, Garrido M, Chan SL, Knox J, Daniele B, Ebbinghaus SW, Chen E, Siegel AB, Zhu AX, Cheng AL; KEYNOTE-240 investigators. Finn RS, et al. Among authors: siegel ab. J Clin Oncol. 2020 Jan 20;38(3):193-202. doi: 10.1200/JCO.19.01307. Epub 2019 Dec 2. J Clin Oncol. 2020. PMID: 31790344 Clinical Trial.
Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment.
Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Llovet JM, et al. Among authors: siegel ab. Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4. Cardiovasc Intervent Radiol. 2022. PMID: 35119481 Free PMC article. Clinical Trial.
Exosome-Mediated Crosstalk between Keratinocytes and Macrophages in Cutaneous Wound Healing.
Zhou X, Brown BA, Siegel AP, El Masry MS, Zeng X, Song W, Das A, Khandelwal P, Clark A, Singh K, Guda PR, Gorain M, Timsina L, Xuan Y, Jacobson SC, Novotny MV, Roy S, Agarwal M, Lee RJ, Sen CK, Clemmer DE, Ghatak S. Zhou X, et al. Among authors: siegel ap. ACS Nano. 2020 Oct 27;14(10):12732-12748. doi: 10.1021/acsnano.0c03064. Epub 2020 Sep 25. ACS Nano. 2020. PMID: 32931251 Free PMC article.
Endoscopic Submucosal Dissection in North America: A Large Prospective Multicenter Study.
Draganov PV, Aihara H, Karasik MS, Ngamruengphong S, Aadam AA, Othman MO, Sharma N, Grimm IS, Rostom A, Elmunzer BJ, Jawaid SA, Westerveld D, Perbtani YB, Hoffman BJ, Schlachterman A, Siegel A, Coman RM, Wang AY, Yang D. Draganov PV, et al. Among authors: siegel a. Gastroenterology. 2021 Jun;160(7):2317-2327.e2. doi: 10.1053/j.gastro.2021.02.036. Epub 2021 Feb 19. Gastroenterology. 2021. PMID: 33610532 Free PMC article.
Avian Inflammatory Markers.
Walton RM, Siegel A. Walton RM, et al. Among authors: siegel a. Vet Clin North Am Exot Anim Pract. 2022 Sep;25(3):679-695. doi: 10.1016/j.cvex.2022.05.002. Vet Clin North Am Exot Anim Pract. 2022. PMID: 36122946 Review.
PPARγ agonist treatment reduces fibroadipose tissue in secondary lymphedema by exhausting fibroadipogenic PDGFRα+ mesenchymal cells.
Chen Z, Ghavimi SAA, Wu M, McNamara J, Barreiro O, Maridas D, Kratchmarov R, Siegel A, Djeddi S, Gutierrez-Arcelus M, Brennan PJ, Padera TP, von Andrian U, Mehrara B, Greene AK, Kahn CR, Orgill DP, Sinha I, Rosen V, Agarwal S. Chen Z, et al. Among authors: siegel a. JCI Insight. 2023 Dec 22;8(24):e165324. doi: 10.1172/jci.insight.165324. JCI Insight. 2023. PMID: 38131378 Free PMC article.
1,267 results